Dendritic cell-targeted VLP vaccine for enhanced anti-tumor immunity
A novel glycan-costumed virus-like particle (VLP) vaccine targets dendritic cell lectins to elicit potent Type 1 anti-tumor responses. This approach enhances long-term tumor protection by activating specific T cell respo...